Cabazitaxel in patients with metastatic castrate-resistant prostate cancer previously treated with a docetaxel-containing regimen: A single U.K. cancer center's experience using Early Access Programme and Cancer Drugs Fund.

Abstract

224 Background: The TROPIC Trial demonstrated improved overall survival in patients with mCRPC who progressed during or after treatment with docetaxel. The trial established cabazitaxel as a tolerable and viable second line treatment option in these patients. We report our experience with cabazitaxel in patients receiving treatment within the Early Access Programme (EAP) and via the Cancer Drugs Fund (CDF). Methods: Retrospective review of patients receiving cabazitaxel chemotherapy from 1st January 2011 to 1st January 2012. Chemotherapy administration was corroborated via the electronic prescribing system. Patient records provided documentation regarding disease response and treatment toxicities. For patients within the EAP, data was confirmed and supplemented via the Trials Office. Results: 22 patients were identified, of which 20 received cabazitaxel. 12 were treated within the EAP and 8 via the CDF. Median age was 68.5 years (59-83) within the EAP group and 70 years (52-78) within the CDF group, whilst median number of cycles was 6 (1-10) and 5.5 (1-8) respectively. 83.3% of EAP patients received full dose throughout, compared with 62.5% of the CDF patients. Primary GCSF was used in 91.6% of EAP patients and 75% of CDF patients, with secondary GCSF in 8.3% and 12.5% respectively. 3/20 patients had treatment discontinued due to progressive disease (after a minimum of 3 cycles). 13/20 patients had a positive biochemical and/or clinical response. 15/20 patients (Gleason score ≥ 8, 7 of 15) remain alive with a mean survival of 12.1 months (3.4-19.4). There were no treatment related deaths. Treatment related adverse events are shown in the Table. Conclusions: Our results are comparable with the TROPIC data, suggesting cabazitaxel offers demonstrable response rates and meaningful survival with an acceptable toxicity profile. [Table: see text]